论文部分内容阅读
目的比较维格列汀、吡格列酮、格列美脲分别与二甲双胍合用治疗2型糖尿病时的效果、成本及成本-效果。方法运用Markov模型对三种治疗方案的终身治疗成本及效用(期望寿命、质量调整寿命年)进行经济学评价,通过文献资料和专家问卷咨询获得临床、生命质量、并发症年治疗成本等数据,进行敏感度分析。结果维格列汀、吡格列酮、格列美脲分别与二甲双胍合用治疗2型糖尿病分别延长11.02、10.96、10.90个质量调整生命年,而生命周期中三种治疗方案的治疗费用分别为124892元、134135元、126010元。敏感度分析证明了结果的可靠性。结论与吡格列酮、格列美脲合并二甲双胍质量相比,维格列汀合并二甲双胍治疗获得的健康效果更好,而治疗成本更低。
Objective To compare the efficacy, cost and cost-effectiveness of vildagliptin, pioglitazone and glimepiride in combination with metformin in the treatment of type 2 diabetes mellitus. Methods The Markov model was used to evaluate the life-long treatment cost and utility (life expectancy and quality adjusted life year) of the three treatment plans. The data of clinical, quality of life and annual treatment costs of complications were obtained through literature review and expert questionnaire consultation. Conduct sensitivity analysis. Results The combination of vildagliptin, pioglitazone and glimepiride with metformin in treatment of type 2 diabetes mellitus extended 11.02, 10.96 and 10.90, respectively, and the treatment costs of the three treatment plans in the life cycle were 124,892 yuan and 134135 respectively Yuan, 126,010 yuan. Sensitivity analysis proves the reliability of the results. Conclusion Compared with the quality of the combination of metformin and pioglitazone and glimepiride, the effect of vildagliptin combined with metformin is better and the cost of treatment is lower.